argenx SE (ARGX) Q1 2025 Earnings Call

Investor webinar replay

Watch the replay and follow the connected company analysis, news, and investor updates for Argenx Se.

Watch the replay

Replay transcript excerpt

WEBVTT 00:00:00.031 -- 00:00:03.516 placed on mute to prevent any background noise. 00:00:03.516 -- 00:00:06.841 After the speaker's remarks, there will be a question and answer session. 00:00:06.841 -- 00:00:10.026 Thank you. I'd now like to introduce 00:00:10.026 -- 00:00:12.729 you may now begin your conference. 00:00:12.729 -- 00:00:18.498 Thank you. A press release was issued earlier today with our first quarter of 2025 financial 00:00:18.498 -- 00:00:23.745 results and business updates. This can be found on our website along with the presentation 00:00:23.745 -- 00:00:29.127 for today's webcast. Before we begin on slide two, I'd like to remind you that forward-looking 00:00:29.127 -- 00:00:31.850 statements may be presented during this call. 00:00:31.850 -- 00:00:36.556 These may include statements about our future expectations, clinical development, regulatory 00:00:36.556 -- 00:00:41.241 timelines, the potential success of our product candidates, financial projections, and 00:00:41.241 -- 00:00:43.043 upcoming milestones. 00:00:43.043 -- 00:00:47.450 Actual results may differ materially from those indicated by the statement. 00:00:47.450 -- 00:00:52.056 Argenix is not under any obligation to update statements regarding the future or to conform 00:00:52.056 -- 00:00:56.342 these statements in relation to actual results unless required by law. 00:00:56.342 -- 00:01:00.868 I'm joined on the call today by Tim Van Hauermeren, Chief Executive Officer, Carl Gubitz, 00:01:00.868 -- 00:01:04.873 Chief Financial Officer, and Kerry Mathey, Chief Operating Officer. 00:01:04.873 -- 00:01:07.917 I'll now turn the call over to Tim. 00:01:07.917 -- 00:01:12.863 Thank you, Beth, and welcome, everyone. I'll begin on slide number three. 00:01:12.863 -- 00:01:16.441 At Argenix, ...